Sophiris Bio Inc.
(NASDAQ : SPHS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.20%83.100.9%$974.49m
KITEKite Pharma, Inc.
0.02%179.3416.1%$742.24m
CELGCelgene Corporation
0.42%144.491.1%$499.80m
AMGNAmgen Inc.
0.08%185.911.1%$483.55m
BIIBBiogen Inc.
-0.17%317.911.2%$421.63m
REGNRegeneron Pharmaceuticals, Inc.
1.46%439.022.7%$359.50m
ALNYAlnylam Pharmaceuticals, Inc
1.71%115.7410.7%$249.91m
ALXNAlexion Pharmaceuticals, Inc.
0.45%143.461.9%$230.00m
JUNOJuno Therapeutics, Inc.
-4.94%42.9114.6%$225.05m
VRTXVertex Pharmaceuticals Incorporated
-1.39%149.161.9%$208.44m
INCYIncyte Corporation
-1.26%109.452.6%$205.03m
ILMNIllumina, Inc.
-0.66%200.083.5%$158.36m
BLUEBluebird Bio, Inc.
1.20%130.3019.3%$143.15m
BMRNBioMarin Pharmaceutical Inc.
-0.83%94.164.4%$136.24m
CLVSClovis Oncology, Inc.
-2.85%76.3218.0%$132.55m

Company Profile

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which develops products for the treatment of urological diseases. It is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded in May 2003 and is headquartered in La Jolla, CA.